Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD) will announce its Q2 2022 financial results on August 9, 2022, post-market close. A conference call led by the senior management team is scheduled for 4:30 p.m. ET to discuss the results and corporate progress. The company focuses on RAS-addicted cancers with a diverse pipeline of RAS(ON) Inhibitors, including RMC-6236 and RMC-6291, among others. The live conference can be accessed via a dedicated webcast.

Positive

• Developing novel targeted therapies for RAS-addicted cancers.
• Diverse pipeline including RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C).

Negative

• None.

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, August 9, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a conference call and webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Conference Call and Webcast Information:

• Dial-in: (800) 715-9871 (U.S. toll free) or (646) 307-1963; conference ID 6539267.
• Live webcast with slides can be accessed at: https://ir.revmed.com/events-and-presentations.

A replay of the webcast will be available on the company’s website shortly after the conference call concludes at https://ir.revmed.com/events-and-presentations and will be archived there for at least 14 days.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS^MULTI) and RMC-6291(KRAS^G12C) are in clinical development. Additional RAS(ON) Inhibitors in development include RMC-9805 (KRAS^G12D) and RMC-8839 (KRAS^G13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Contact Information

David S. Arrington
SVP Investor Relations & Corporate Affairs
Revolution Medicines
650-452-6046
darrington@revmed.com

FAQ

When will Revolution Medicines report its Q2 2022 financial results?

Revolution Medicines will report its Q2 2022 financial results on August 9, 2022, after market close.

What time is the conference call for Revolution Medicines Q2 results?

The conference call for Revolution Medicines' Q2 results is scheduled for 4:30 p.m. ET on August 9, 2022.

Where can I access the webcast for Revolution Medicines' financial results?

The live webcast for Revolution Medicines' financial results can be accessed at https://ir.revmed.com/events-and-presentations.

What are the key products in Revolution Medicines' pipeline?

Key products in Revolution Medicines' pipeline include RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C).